- Research article
- Open Access
- Open Peer Review
Patients’ and physicians’ perceptions and attitudes about oral anticoagulation and atrial fibrillation: a qualitative systematic review
BMC Family Practice volume 18, Article number: 3 (2017)
Oral anticoagulant therapy reduces the risk of stroke in patients with atrial fibrillation, but many patients are still not prescribed this therapy. The causes of underuse of vitamin K antagonists oral anticoagulants are not clear but could be related, in part, to patients’ and physicians’ perceptions and attitudes towards the benefits and downsides of this treatment. The purpose of this systematic review was to evaluate and synthesize patients’ and physicians’ perceptions and attitudes towards the benefits and downsides of vitamin K antagonist, in order to explore potential factors related with its underuse.
We included studies that used qualitative or mixed methods and focused on patients’ and/or physicians’ perceptions and attitudes towards oral anticoagulation. We systematically searched PubMed, EMBASE, ISI WoK, and PsycINFO from their inception until May 2013. Two reviewers independently assessed the quality of the included studies and synthesized results using a thematic analysis approach.
We included a total of nine studies. In four studies, the quality assessed was excellent and in five was moderate. We identified three themes that were of interest to both physicians and patients: information to reinforce anticoagulation use, balance of benefits and downsides, roles in decision-making and therapy management. Three additional themes were of interest to patients: knowledge and understanding, impact on daily life, and satisfaction with therapy. The main difficulties with the use of anticoagulant treatment according to physicians were the perceived uncertainty, need of individualised decision-making, and the feeling of delegated responsibility as their main concerns. The main factors for patients were the lack of information and understanding.
Physicians’ and patients’ perceptions and attitudes might be potential factors in the underuse of treatment with vitamin K antagonists. Improving the quality and usability of clinical guidelines, developing tools to help with the decision-making, enhancing coordination between primary care and hospital care, and improving information provided to patients could help improve the underuse of anticoagulation.
Atrial fibrillation or flutter is a common cardiac disorder. Estimated prevalence of patients with atrial fibrillation was 33.5 million people worldwide in 2010, of which 20.9 million were men and 12.6 million were women . Incidence and prevalence are higher in developed countries and their estimated trends are growing due to population aging [1, 2]. Age-adjusted mortality in 2010 was 1.6 and 1.7 per 100,000 for men and women, respectively .
A high risk of stroke is associated with atrial fibrillation [3–5]. Of all patients that suffer an stroke 20–30% have atrial fibrillation . Age, a history of previous embolism, heart failure, type 2 diabetes mellitus, hypertension arteriopathy, and female sex are factors that increase the risk of embolism among patients with atrial fibrillation [7, 8]. Atrial fibrillation is a health issue that is costly for the healthcare system. Costs derive mainly from hospital admissions (50%) and treatment prescription (20%) . Moreover, non-treated patients experience more complications compared to treated patients leading to obvious economic consequences .
Vitamin K antagonists oral anticoagulants (VKAs) significantly reduce the risk of stroke in patients with atrial fibrillation [8, 11], and are the main group of drugs that has been historically used for such patients. Nevertheless, treatment with VKAs is relatively complex due to its narrow therapeutic range, which urges regular monitorization of the International Normalised Ratio to place the patient within the optimal range for anti-thrombotic protection without excessive risk of haemorrhage [6, 12]. Furthermore, VKAs show various drug interactions and, therefore, no big changes are to be made in the intake of vitamin K-rich foods. Such specificities of the treatment with VKAs are some of the potential reasons for its underuse [13–17] despite concluding evidence available on its potential net benefit [12, 18].
A new group of oral anticoagulants has recently emerged as a therapeutic alternative for patients with atrial fibrillation: the direct oral anticoagulants (DOACs). Patients taking DOACs show lower risk of stroke, intracranial bleeding, haemorrhage or death, but higher risk of gastrointestinal bleeding compared to patients receiving VKAs . Additionally, patients taking DOACs show fewer interactions with other drugs and no interactions with food. However, their effect has a shorter duration, there is no known antidote and are not recommended for patients with an important kidney condition. Moreover, DOACs are considerably more expensive than VKAs, which is an essential feature to ensure equal access and treatment adherence . Although the absence of laboratory monitoring for DOACs might be attractive for patient, it also entails potential disadvantages, such as the inability to measure the level of anticoagulation, determine treatment adherence, or detect potential drug interactions . Nowadays, VKAs continue to be the group of drugs more frequently used in the common practice for patients with atrial fibrillation .
Previous studies show that preferences of patients’ with atrial fibrillation may be an important reason for underutilization of oral anticoagulation [23–25]. The previous systematic review  that examined experiences of patients and health providers regarding atrial fibrillation and treatment with VKAs, revealed a few factors that might be related to underutilization of VKAs. Nevertheless, there is no qualitative systematic review to date focused on knowing patients’ and physicians’ perceptions and attitudes towards VKAs that might be potential factors for underutilization of VKAs for atrial fibrillation.
The objective of this qualitative systematic review is to identify potential factors associated with underuse of VKAs oral anticoagulants. To do so, we critically synthesised the available qualitative research evidence about patients’ and physicians’ perceptions and attitudes towards this treatment alternative.
We conducted a systematic review to synthesize findings from studies that assessed patients’ and physicians’ attitudes and perceptions of the risks, benefits, and use of vitamin K antagonists oral anticoagulants (VKAs), in order to explore the perceptions and attitudes related to the underuse of anticoagulation in patients with atrial fibrillation.
Systematic review of qualitative research.
We searched PubMed, EMBASE, ISI Web of Knowledge (ISI WoK) and PsycINFO from their inception until May 2013. In order to identify relevant publications, a search using a combination of key words “values or preferences”, “anticoagulants”, and “atrial fibrillation” was performed. The search strategy used is in Additional file 1.
Two authors independently assessed the references retrieved from the search and later resolved any disagreements. We included: i) original articles that explored the perceptions and attitudes of patients, physicians, or both, about VKAs for atrial fibrillation; ii) used qualitative or mixed methods; and iii) were published in English, Spanish, German, or French. We excluded studies that only explored perceptions and attitudes of health professionals other than physicians, and studies that did not include qualitative results.
We assessed the quality of studies using the Critical Appraisal Skills Programme (CASP) tool for qualitative studies .
Data extraction and data synthesis
We collected the main characteristics of each study included in the review (Table 1). We contacted the authors of the included studies for clarification. We used a thematic analysis to analyze the data . The main and recurrent themes, as well as categories, across the studies were collected systematically. We segmented the themes and contrasted them between studies, collapsing and refining the categories per type of participant (patients and physicians) until the final result was deemed optimal.
We initially retrieved 1147 references. A total of 1134 publications were excluded after reading the title and abstract, and 4 were excluded after reading the full text (Fig. 1). A total of nine articles corresponding to eight studies were included [28–36]. We also included a still unpublished study conducted by our group . Two of the nine studies collected data both from patients and physicians [29, 37], four collected data from patients only [28, 32, 33, 35], and three from physicians only [31, 34, 36]. In four studies, the quality assessed was excellent [29–31, 35, 37] and in five was moderate [28, 32–34, 36].
Physicians’ perceptions and attitudes
The five studies with physicians as participants [29, 31, 34, 36, 37] (Table 1) included a total of 91 physicians (family physicians, cardiologists, geriatrics and internal medicine physicians). The three main themes that emerged from the analysis were: I) information to reinforce anticoagulation use; II) balance of benefits and downsides; and III) roles in decision-making and therapy management (Fig. 2).
Information to reinforce anticoagulation use
In three studies [29, 31, 37], some physicians considered the scientific evidence about VKAs was a possible barrier for the correct management of anticoagulation due to the constant changes in the literature . Some expressed concerns and others justified the prescription of aspirin rather than warfarin . Some referred to their lack of skills in using evidence-based medicine . They also expressed concerns regarding the applicability of the evidence, which they considered did not include representative populations, and did not reflect daily practice . Other comments referred to the need for more information to reinforce the decision to start the VKAs , the finding of ambiguities in the published clinical guidelines , and the importance of individualized decision-making for each patient [31, 37].
In one study , physicians stated that they often gave more weight to their own professional experience than to research findings for decision-making in VKAs. In relation to what information physicians should provide to patients, in one study the opinions ranged on the grade of information provided , although in another study there was consensus that generally the way information was given to patients was inappropriate  (Table 2).
Balance of benefits and downsides
Most of the studies discussed the balance of the benefits and downsides [29, 34, 36, 37]. Physicians expressed no doubts about the benefits of VKAs . In the Bajorek study , however, geriatricians appeared to be more focused on the risks than on the benefits. Some physicians expressed uncertainty in specific cases, such as psychiatric patients, polymedicated patients, patients that fail to attend follow up, patients at risk of falls [34, 37], the elderly, and also in certain social environments [36, 37] as alcoholic patients .
Some family physicians related their uncertainty in the decision-making of anticoagulation, not only to evidence but also to the experiences  and reactions manifested by the patients . Some physicians attributed this patient negativity to the lack of adequate information  or opinions based on hearsay . In one study , physicians’ main concerns about VKAs were the risk of bleeding and the International Normalized Ratio monitoring.
Only in one study , the physicians directly raised the topic of safety. Of note, most of the physicians did not show excessive concerns about safety. Family physicians who were especially concerned about safety described a lack of clarity in the protocols on safety and in the International Normalized Ratio monitoring. Additionally they felt that often the person ultimately responsible for the treatment was unclear (Table 2).
Roles in decision-making and therapy management
In all studies [29, 31, 34, 36, 37], physicians discussed decision-making. In three studies [31, 34, 37], most physicians supported shared decision-making; however, the degree of involvement varied . They stated that the clearer the evidence, the less they involved patients in decision-making [34, 37]. In two studies, physicians stated that patients preferred to delegate to them [29, 37]. However, they stressed that patients themselves needed to assume responsibility for their management [29, 37]. Even some hospital physicians proposed daily International Normalized Ratio self-monitoring as the best option for the patient because it implies a more sustained control .
Family physicians also felt specialized physicians delegated responsibility of a complex therapy, traditionally assigned to hospital professionals . Some family physicians disagreed on the indications for VKAs given by hospital physicians [29, 31, 37]. They considered this disagreement could be associated with the differences in approach to decision-making: primary care physicians support patient-centered decision-making, while other specialists are more disease-centered [31, 37]. They also recognized a lack of confidence and experience prescribing and controlling VKAs, and communication difficulties with other specialists in case of doubt, due to the lack of communication channels . Some specialized physicians also recognized this lack of communication  and suggested that there should be more communication between primary care and hospitals to reach a consensus on the indications . Some specialized physicians stated that they also considered non-clinical characteristics of the patients, such as psychosocial characteristics  (Table 2).
Patients’ perceptions and attitudes
In the six studies that included patients [28–30, 32, 33, 35, 37] (Table 1) six main themes emerged (Fig. 2): I) knowledge and understanding; II) information to reinforce anticoagulation use; III) impact of the therapy on daily living; IV) balance of benefits and downsides; V) roles in decision-making and therapy management; and VI) satisfaction with therapy.
Knowledge and understanding
In four studies [28, 30, 33, 35] patients discussed the knowledge and understanding of VKAs, varying with patient age (it was higher among younger patients) , condition (lower in patients with atrial fibrillation than in those with thromboembolism), and setting (lower in patients from Spain than in patients from the United Kingdom or the United States of America) . Most patients of two studies were unaware that VKAs prevents stroke [28, 30, 35] and in one particular study they did not relate with the risk of stroke nor with atrial fibrillation . They did not associate International Normalized Ratio monitoring with the risk of bleeding or stroke. Only patients who had had a stroke had full knowledge of the indications for anticoagulation .
Patients expressed some misconceptions, hearsay [30, 33], and myths  about alcohol consumption, nutrition, and concurrent medication [30, 33]. These misunderstandings were likely caused by contradictory recommendations made by other patients, caregivers, and health care professionals . Some reported that they had been informed that VKAs was “a sort of rat poison”  (Table 3).
Information to reinforce anticoagulation use
In four studies [29, 30, 35, 37] patients discussed the information they had received to reinforce VKAs use, with variable needs on the amount of information they wanted to receive . In two studies [29, 35], some patients taking VKAs considered the amount of information received was insufficient. They felt that the information should be more detailed, especially concerning drug functioning and dose adjustments [29, 30]. They requested more information about the role and importance of VKAs, and the implications in accepting this treatment, at the time of the decision-making . In another study, patients considered there was a lack of both written and verbal communication .
Patients also manifested difficulties in applying the knowledge during the daily management of their treatment, and felt they were “on their own” . They would have preferred to receive the information gradually during follow-up and to be able to check if they had understood correctly , increasing their confidence in its management [29, 30] (Table 3).
Impact of the therapy on daily living
In four studies [30, 33, 35, 37], the issue about the impact of therapy on daily living emerged. In one study , in which the participants had been taking warfarin, they discussed about the impact of VKAs and stated that it was small for most of them. Factors which most concerned patients were: daily management of VKAs [30, 33, 35, 37] (dietary restrictions, interactions with other drugs and alcohol consumption), monitoring, the risk of bleeding [30, 33, 35], the bruises that made them look older, limitations in certain activities such as sports, gardening or travelling . Some patients stressed the changes they had made in their daily lives in order to manage VKAs [30, 33, 35]. Regarding monitoring, some patients stated that it provided them the feeling of greater control of the disease, while others reported that it made them feel calm. However, the more frequently the monitoring takes place, the greater the perception of the burden is  (Table 3).
Balance of benefits and downsides
In all the studies with patients as participants [28, 30, 32, 33, 35, 37], they discussed the benefits and downsides. The benefits that some patients associated with VKAs were: assurance of treatment success, stroke prevention  and a chance to live longer . Patients tended to choose VKAs when they perceived a risk of stroke  or when they had a better understanding of the conditions associated with anticoagulation (serious and mild stroke, major bleeding, and the economic costs and disadvantages of VKAs and aspirin) . In general, patients who had not taken VKAs based their opinions on experiences of family members [32, 37], friends , and acquaintances . One study  showed that most patients accepted the therapy, monitoring, dose changes and compliance with the therapy. However, some patients  considered VKAs treatment was ineffective, and those who had not suffered a stroke or were receiving the therapy for the first time were more skeptical.
In five studies, the risks of therapy perceived by the patients were bleeding [30, 32, 33, 35, 37], hematomas , and other adverse effects . In three studies [30, 33, 35], some patients taking VKAs explained that they had major bleeding [30, 33, 35]. Two studies [33, 35] specified that only the minority of participants had this complication. Regarding bleeding, most patients in one study  expressed no fear of major bleeding but others expressed anxiety . In two studies some patients expressed initial fear [30, 37].
In one study , patients described thrombotic and hemorrhagic stroke as a complex condition with serious or irreversible effects, and they considered it was more important than major bleeding, economic costs, and the disadvantages of VKAs and aspirin. In another study, they considered that hemorrhagic stroke was a final and permanent state . These perceptions were based on the experience of family members and friends [32, 37] or on their own experience  (Table 3).
Roles in decision-making and therapy management
In three studies, the patients discussed roles in decision-making and therapy management [30, 35, 37]. In one study , patients stated that anticoagulation was the responsibility of both physicians and patients; however, patients felt that they alone assumed the responsibility of therapy. In two studies, most patients acknowledged that decision-making was carried out by the physician only [35, 37]. This unilateral decision was related to: I) the patient’s high level of confidence in the physician experience , II) a paternalistic physician-patient relationship in which the patients were (also) reluctant to take an active role; and III) the idea that the professionals were trained and could be more objective . In one study , some patients adopted the position of ignorance and delegated the decision to the professional. For a small group of patients in one study, the circumstances in which this therapy was initiated, as a medical emergency, prevented any significant patient involvement  (Table 3).
Satisfaction with therapy
Satisfaction emerged in three studies [29, 30, 35]. In one study, patients recognized that their satisfaction improved when information was given to them individually and was focused on care . In another study, they expressed satisfaction with primary care staff . Dissatisfaction also appeared in several studies. Patients expressed dissatisfaction with the lack of information [29, 35], the quality and level of the information provided by the family physicians , the difficulties and costs related to monitoring , and health professionals’ lack of knowledge of their medical history  (Table 3).
In this systematic review evaluating patients and physicians’ perceptions and attitudes towards vitamin K antagonists (VKAs), we identified several themes which could explain the underuse of VKAs. Physicians regard uncertainty in specific cases, the need of individualized decision-making, and the delegated responsibility in decision making as the main difficulties for using VKAs, while patients noted the lack of information and understanding of VKAs therapy as their main concerns.
Our results in the context of previous research
Three themes –information to reinforce VKAs use, balance of benefits and downsides, and roles in decision-making and therapy management– were common to patients and physicians. The first two themes were closely related from the perspective of physicians. Some of them reported uncertainty regarding the balance between benefits and downsides of VKAs in cases such as polymedicated patients or in patients at high risk of falls [34, 37]. Despite the availability of guidelines and research evidence, some physicians considered that this information did not always clarify their doubts  in a treatment with narrow therapeutic margins . They identified ambiguities in some of the guidelines, and stated that the included populations were not necessarily representative of the very elderly, the main candidates for anticoagulation . The participant physicians suggested the development of individualized decision-making tools as a strategy to improve this uncertainty .
The information to reinforce VKAs use was also related with decision-making and therapy management roles, both of patients and physicians. Some of the physicians and most of the patients stated that the actual decision was generally carried out by physicians only [29, 35, 37], and that the information received was often inadequately provided  and insufficient [29, 35]. Moreover, in one study some family physicians felt that specialized physicians delegated the responsibility of decision making to them. These two sources of delegation were perceived by family physicians as a burden. To address patient’s delegation, the use at the point of care of interactive decision aids linked to guidelines could be a potential strategy . The feeling of family physicians that specialized physicians delegated the responsibility of decision making to them could be explained by the lacking certainty about the treatment and the inadequate exchange of information between them.
A systematic review by Borg et al. that explored patients’ and health professionals’ experiences on VKAs therapy, raised the debate of the discrepancy in the perception that patients and health care professionals have about the decision-making models used in practice . Patients’ experiences suggested a mixed of a paternalistic and interpretative model (the physician take the decision, considering the patient’s values and preferences), while some physicians stated that they practiced shared decision-making. Our systematic review also observed this discrepancy to some extent, suggesting that shared decision–making is not really taking place in clinical practice.
Knowledge and understanding of the therapy was an important issue that arose among patients only. One study included in our systematic review shows that the knowledge and understanding was worse in elderly patients than younger . Given that most patients with atrial fibrillation are of advance age, to be able to make an informed decision, it is especially important that the information is provided and explained appropriately. Moreover, it is crucial to improve the quality of the information provided to patients because it is the main factor of dissatisfaction with the therapy [12, 27, 30]. Better information will improve understanding and is likely to increase the use of anticoagulation . One of the factors that may explain why the difficulties with understanding of the anticoagulant treatment are greater for the elderly is that they generally are less educated , although this fact is changing.
Like one of our studies shows, patients tend to choose treatment with VKAs when they have a better understanding of the conditions associated with anticoagulation . Therefore, understanding of the treatment with VKAs is essential for patients to assess the benefits and downsides based on their preferences .
A previous systematic review of quantitative studies that evaluated patients’ preferences for anticoagulants including direct oral anticoagulants (DOACs), agrees with our review that, considering the different anticoagulant treatments, patients’ preferences are based mainly on clinical aspects (reduction in the risk of stroke and moderate increase in the risk of bleeding). Nevertheless, whenever the different treatment options offer similar security and efficacy, convenience takes on importance for the decision making, such as once-a-day administration or no interactions with drugs or food. The need for monitorization of VKAs is sometimes perceived positively and sometimes negatively .
Limitations and strengths
The main limitation of our study is that we cannot confirm a relationship between the factors identified and underuse of VKAs therapy . Another limitation was that there were two studies which did not only included physicians and patients as participants –nurses, pharmacist, and carers participated too. Only in some cases we were able to exclude the data coming from participants other than our target groups [29, 30, 36]. Also, in one of the studies  it was not always possible to differentiate between patients and physicians for some of the results reported.
The review does not include studies on patients’ perceptions and attitudes towards DOACs. Nevertheless, treatment with VKAs continues to be the main group of drugs used. Additionally, a great part of the emerging deficits in the treatment with VKAs would be applicable to the treatment with DOACs, since said deficits are more related to the healthcare systems, like the lack of information provided to patients or difficulties with the coordination between primary care and hospital care.
Finally, a potential limitation is the fact that further data sources like CINAHL have not been searched. However, we believe that this may be a minor limitation since we have searched biomedical data sources with a wider and more detailed scope.
The main strength of our review is that it is the first qualitative systematic review to specifically explore factors potentially related to the underuse of oral anticoagulation in atrial fibrillation. Moreover, our review includes two more studies [36, 37] than Borg’s systematic review . Another strength of our work is the research team expertise, as it includes a multidisciplinary group of experts in oral anticoagulation therapy, Evidence-Based Medicine, and qualitative research. The group also includes several authors of one of the included studies.
Implications for practice and research
To tackle the underuse of anticoagulation there is a need to improve the quality and usability of clinical guidelines, and of the information that is provided to patients; as well as to enhance the coordination between primary care and hospital care. Linking evidence-based guidelines with decision aids could be a way forward to engage patients and physicians in shared decision-making . Both guidelines and tools should be user-friendly, interactive, and based on the most rigorous evidence.
We identified some of the differences between family physicians and specialized physicians. However, further studies are needed to explore in more depth this issue. Moreover, qualitative studies evaluating the perceptions and attitudes about the direct anticoagulants should also be carried out.
Physicians perceived uncertainty, need of individualized decision-making, and the feeling of delegated responsibility, as their main concerns that may be related to underuse of vitamin K antagonists, while for patients the main factors were the lack of information and understanding. Improving the quality and usability of clinical guidelines, the information provided to patients (e.g. linking decision aids and guidelines), developing tools to facilitate shared decision-making, and enhancing the coordination between primary care and hospital care could help improve the underuse of this important treatment option in patients with atrial fibrillation.
Direct oral anticoagulant
Vitamin K antagonist
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty Jr JH, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47.
Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142–7.
Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.
Cairns JA, Connolly SJ. Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. Circulation. 1991;84(2):469–81. Review.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147(9):1561–4.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M,Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with thespecial contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016 Aug 27.
Tsai LM, Chen JH, Tsao CJ. Relation of left atrial spontaneous echo contrast with prethrombotic state in atrial fibrillation associated with systemic hypertension, idiopathic dilated cardiomyopathy, or no identifiable cause (lone). Am J Cardiol. 1998;81(10):1249–52.
Boysen G, Connolly S, Esekowitz M, Hart R, James K, Kistler P, Kronmal R, Petersen P, Singer D. Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation Analysis of Pooled Data From Five Randomized Controlled Trials. Arch Intern Med. 1994;154(13):1449–57.
Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart. 2004;90(3):286–92. Erratum in: Heart. 2007 Nov;93(11):1472. Murphy, N [corrected to Murphy, N F].
Casciano JP, Dotiwala ZJ, Martin BC, Kwong WJ. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. J Manag Care Pharm. 2013;19(4):302–16.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland Jr JC, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.
Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Turpie AG, van Eickels M, Misselwitz F, Rushton-Smith S, Kayani G, Wilkinson P, Verheugt FW, GARFIELD Registry Investigators. Risk p, 14rofiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013;8(5):e63479.
Tulner LR, Van Campen JP, Kuper IM, Gijsen GJ, Koks CH, Mac Gillavry MR, van Tinteren H, Beijnen JH, Brandjes DP. Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Aging. 2010;27(1):39–50.
Bungard T, Ghali W, Teo K, McAlister F, Tsuyuki R. Why do patients with atrial fibrillation not receive warfarin? Arch Int Med. 2000;160:41–6.
Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet. 1998;352:116771.
Lip GY, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract. 1997;47(418):285–9.
Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ, American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):546S–92S.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. doi:10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.
Wadhera RK, Russell CE, Piazza G. Cardiology patient page. Warfarin versus novel oral anticoagulants: how to choose? Circulation. 2014;130(22):e191–3.
Smith K. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation. London New Drugs Group APC/DTC Briefing. August 2011. [cited May 2012]. Available from: www.sps.nhs.uk/wp-content/uploads/2011/08/DabigatranSPAF.pdf.
Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.
Wilke T, Groth A, Pfannkuche M, Harks O, Fuchs A, Maywald U, Krabbe B. Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use. J Thromb Thrombolysis. 2015;40(1):97–107.
Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, Maywald U, Kohlmann T, Feng YS, Breithardt G, Bauersachs R. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost. 2012;107(6):1053–65.
Borg Xuereb C, Shaw RL, Lane DA. Patients’ and health professionals’ views and experiences of atrial fibrillation and oral-anticoagulant therapy: a qualitative meta-synthesis. Patient Educ Couns. 2012;88(2):330–7.
CASP International Network. Critical appraisal skills programme (CASP). Making sense of evidence about clinical effectiveness. 2010. [cited May 2012] http://www.casp-uk.net/checklists.
Carlsen B, Glenton C, Pope C. Thou shalt versus thou shalt not: a meta-synthesis of GPs’ attitudes to clinical practice guidelines. Br J Gen Pract. 2007;57(545):971–8. doi:10.3399/096016407782604820. Review.
Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. Br Med J. 1999;318:1324–7.
Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I. Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers. Med J Aust. 2007;186(4):175–80.
Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I. Balancing risk versus benefit: the elderly patient’s perspective on warfarin therapy. Pharm Pract. 2009;7(2):113–23.
Lipman T, Murtagh MJ, Thomson R. How research-conscious GPs make decisions about anticoagulation in patients with atrial fibrillation: a qualitative study. Fam Pract. 2004;21(3):290–8.
Fuller R, Dudley N, Blacktop J. Avoidance hierarchies and preferences for anticoagulation-semi-qualitative analysis of older patients’ views about stroke prevention and the use of warfarin. Age Ageing. 2004;33(6):608–11.
Wilt D, Murray M, Donatti C. Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain. Expert Rev Pharmacoecon Outcomes Res. 2009;9(5):467–474(8).
Anderson N, Fuller R, Dudley N. ‘Rules of Thumb’ or reflective practice? Understanding senior physicians’ decision-making about anti-thrombotic usage in atrial fibrillation. Qjm an Int J Med. 2007;100(5):263–9.
Dantas GC, Thompson BV, Manson JA, Tracy CS, Tracy US, Upshur REG. Patients’ perspectives on taking warfarin: qualitative study in family Practice. BMC Fam Pract. 2004;5:15.
Decker C, Garavalia L, Garavalia B, et al. Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians. J Multidiscip Healthc. 2012;5:129–35.
Alonso-Coello P, Montori VM, Solà I, Schünemann HJ, Devereaux P, Charles C, Roura M, Díaz MG, Souto JC, Alonso R, Oliver S, Ruiz R, Coll-Vinent B, Diez AI, Gich I, Guyatt G. Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a two-phase study. BMC Health Serv Res. 2008;8:221. doi:10.1186/1472-6963-8-221.
Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–645.e4.
Algoritsas T, Heen AF, Brandt L, Alonso-Coello P, Kristiansen A, Akl EA, Neumann I, Tikkinen KA, Weijden T, Elwyn G, Montori VM, Guyatt GH, Vandvik PO. Decision aids that really promote shared decision making: the pace quickens. BMJ. 2015;350:g7624.
Hernández Madrid A, Potpara TS, Dagres N, Chen J, Larsen TB, Estner H, Todd D, Bongiorni MG, Sciaraffia E, Proclemer A, Cheggour S, Amara W, Blomstrom-Lundqvist C. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace. 2016;18(3):463–7.
Wilke T, Bauer S, Mueller S, Kohlmann T, Bauersachs R. Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. Patient. 2016 Jul 26.
Carlsen B, Norheim OF. “What lies beneath it all?”--an interview study of GPs’ attitudes to the use of guidelines. BMC Health Serv Res. 2008;8:218.
We would like to thank Ms Carolyn Newey, Ms Andrea Cervera Alepuz and Ms María Victoria Leo Rosas for their invaluable help editing the manuscript.
The study is sponsored through a governmental grant of the Instituto de Salud Carlos III, Spanish Ministry of Health (grant No. PI06/90391).
Availability of data and materials
IS conducted the literature searches. ESA and BEM screened searched results and selected the studies for inclusion. GMD, ESA, BEM and SPS analyzed the data extraction. GMD and PAC drafted the initial version. ESA, BEM, IS and SPS review critically the manuscript. All authors read and approved the final version.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
About this article
Cite this article
Mas Dalmau, G., Sant Arderiu, E., Enfedaque Montes, M.B. et al. Patients’ and physicians’ perceptions and attitudes about oral anticoagulation and atrial fibrillation: a qualitative systematic review. BMC Fam Pract 18, 3 (2017) doi:10.1186/s12875-016-0574-0
- Atrial fibrillation
- Oral-anticoagulation therapy
- Systematic Review
- Qualitative Research